The Proof Line
Consolidation tracker
Acquisitions and alliances do not remove clinical research work. They change who controls it. This register follows each transaction we are covering, what moves with it, and the latest milestone reported so far.
Read the full analysis in Clinical research consolidation does not remove the work.
Tracked transactions
Fortrea
CRO, acquiring early-phase infrastructure
Announced, not yet closed
Latest milestone 02-SEP-2026
Agreed to acquire Worldwide Clinical Trials' Early Phase Services division for approximately $45 million.
What moves
- A 200-bed clinical pharmacology unit in San Antonio
- A GLP bioanalytical laboratory in Austin
- A biospecimen-storage facility in Pflugerville, Texas
- Early-phase project delivery, quality oversight and sponsor relationships
Milestones
- 02-SEP-2026 Acquisition of the Early Phase Services division announced. Transition arrangements described as intended to preserve continuity for employees, customers and ongoing programs.
Source: Fortrea acquisition announcement, September 2, 2026
Worldwide Clinical Trials
CRO, divesting early phase
Announced, not yet closed
Latest milestone 02-SEP-2026
Divesting its Early Phase Services division and directing investment toward later-stage therapeutic delivery.
What moves
- Investment focus toward oncology, neuroscience, internal medicine and rare disease
- Later-stage delivery capability retained; early-phase infrastructure transfers to Fortrea
Milestones
- 02-SEP-2026 Sale of the Early Phase Services division to Fortrea announced, alongside stated intent to concentrate capital on later-stage work.
Source: Fortrea acquisition announcement, September 2, 2026
Vertex and Crinetics Pharmaceuticals
Sponsor acquiring clinical-stage programs
Completed
Latest milestone 01-SEP-2026
Vertex completed its approximately $10 billion acquisition of Crinetics Pharmaceuticals.
What moves
- An approved endocrine product
- Atumelnant, in Phase 3 development for congenital adrenal hyperplasia
- Atumelnant, in Phase 2 development for Cushing's syndrome
Milestones
- 01-SEP-2026 Acquisition completed.
Source: Vertex acquisition completion, September 1, 2026
Lilly and Merida Biosciences
Sponsor acquiring clinical-stage programs
Announced, not yet closed
Latest milestone 31-AUG-2026
Lilly agreed to acquire Merida Biosciences for up to $2.875 billion.
What moves
- Merida's lead precision-immunology program, already in Phase 1 development
Milestones
- 31-AUG-2026 Agreement to acquire announced.
Source: Lilly agreement to acquire Merida, August 31, 2026
BioMarin and Alesta Therapeutics
Sponsor acquiring clinical-stage programs
Completed
Latest milestone 01-SEP-2026
BioMarin completed its acquisition of Alesta Therapeutics.
What moves
- An ongoing Phase 1/2a rare-disease program
Milestones
- 01-SEP-2026 Acquisition completed.
Source: BioMarin acquisition completion, September 1, 2026
Tigermed and Veeda Lifesciences
Regional CRO alliance
Alliance, no change of ownership
Latest milestone 03-SEP-2026
Announced a coordinated China-India clinical research corridor. Ownership structures remain separate; the operating proposition becomes more integrated.
What moves
- Coordinated governance across two research markets
- Harmonized data standards
- Services spanning preclinical development through Phase IV
Milestones
- 03-SEP-2026 Alliance announced.
Source: Tigermed and Veeda alliance, September 3, 2026
Each entry restates what was publicly announced on the date shown. Where a transaction has not closed, the tracker says so rather than assuming the outcome.